OXYPHENBUTAZONE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Oxyphenbutazone, and what generic alternatives are available?
Oxyphenbutazone is a drug marketed by Watson Labs and is included in one NDA.
The generic ingredient in OXYPHENBUTAZONE is oxyphenbutazone. There is one drug master file entry for this compound. Additional details are available on the oxyphenbutazone profile page.
Summary for OXYPHENBUTAZONE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 57 |
Clinical Trials: | 1 |
Patent Applications: | 4,093 |
Formulation / Manufacturing: | see details |
DailyMed Link: | OXYPHENBUTAZONE at DailyMed |
Recent Clinical Trials for OXYPHENBUTAZONE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 |
Federal University of São Paulo | Phase 4 |
Medical Subject Heading (MeSH) Categories for OXYPHENBUTAZONE
Anatomical Therapeutic Chemical (ATC) Classes for OXYPHENBUTAZONE
US Patents and Regulatory Information for OXYPHENBUTAZONE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Watson Labs | OXYPHENBUTAZONE | oxyphenbutazone | TABLET;ORAL | 088399-001 | Sep 17, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |